Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients.
暂无分享,去创建一个
Lawrence Corey | Anna Wald | Kieren A Marr | A. Wald | L. Corey | K. Marr | F. Crippa | R. Carter | Rachel A Carter | Fulvio Crippa
[2] I. Marino,et al. Infections due to dematiaceous fungi in organ transplant recipients: case report and review. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[3] Lloyd D. Fisher,et al. 2. Biostatistics: A Methodology for the Health Sciences , 1994 .
[4] M. Levenstein,et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study. , 1995, The Journal of infectious diseases.
[5] S. Heimfeld,et al. Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. , 1999, Blood.
[6] M. Boeckh,et al. Infectious complications after autologous CD34-selected peripheral blood stem cell transplantation. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[7] D. Kontoyiannis,et al. Zygomycosis in the 1990s in a tertiary-care cancer center. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[8] G. Alangaden,et al. Antifungal prophylaxis with low-dose fluconazole during bone marrow transplantation. The Bone Marrow Transplantation Team. , 1994, Bone marrow transplantation.
[9] E. Anaissie,et al. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. , 1997, Blood.
[10] J. Latgé,et al. Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[11] J. Ribes,et al. Zygomycetes in human disease. , 2000, Clinical microbiology reviews.
[12] M. Boeckh,et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. , 2000, Blood.
[13] R. Storb,et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. , 1996, Blood.
[14] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[15] R Sylvester,et al. An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. , 1998, The Journal of infection.
[16] T. C. White,et al. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. , 2000, The Journal of infectious diseases.
[17] D. Denning,et al. Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection. , 1997, The Journal of antimicrobial chemotherapy.
[18] W. Leisenring,et al. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. , 1997, The Journal of infectious diseases.
[19] V. Yu,et al. Cirrhotic fever in the 1990s: a prospective study with clinical implications. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[20] V. Morrison,et al. Non-Candida fungal infections after bone marrow transplantation: risk factors and outcome. , 1994, The American journal of medicine.
[21] A. Nagler,et al. Invasive fungal sinusitis in patients undergoing bone marrow transplantation. , 1993, Bone marrow transplantation.
[22] J. Perfect,et al. The new fungal opportunists are coming. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[23] R. Storb,et al. Effects of treatment regimens in patients allografted for acute and chronic myelogenous leukemia. , 1991, Bone marrow transplantation.
[24] P. Cernoch,et al. Dematiaceous fungi are an increasing cause of human disease. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[25] Y. Ohnishi,et al. Alteration of Cell Wall Composition Leads to Amphotericin B Resistance in Aspergillus flavus , 1999, Microbiology and immunology.
[26] W. Leisenring,et al. The Effect of Prophylactic Fluconazole on the Clinical Spectrum of Fungal Diseases in Bone Marrow Transplant Recipients with Special Attention to Hepatic Candidiasis: An Autopsy Study of 355 Patients , 1998, Medicine.
[27] Yvonne M Clayton,et al. Book Review: Medically Important Fungi: A Guide to Identification , 1977 .
[28] S. Sanche,et al. In Vitro Amphotericin B Resistance in Clinical Isolates of Aspergillus terreus, with a Head-to-Head Comparison to Voriconazole , 1999, Journal of Clinical Microbiology.
[29] D. Denning,et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[30] H. Deeg,et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. , 1994, Blood.